Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 4/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.46 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20074215 | 0.86 | ACACB (0.51) | — | |
| SCHEMBL12302732 | 0.86 | LDHA (0.53) | LDHAHTTKMT2AFPR2F2RL1 | |
| SCHEMBL12467245 | 0.85 | ACACB (0.56) | LDHAKMT2AFPR2 | |
| SCHEMBL14942967 | 0.84 | LDHA (0.57) | LDHAMMP1SAE1UBA2MMP3 | |
| SCHEMBL13033619 | 0.84 | LDHA (0.57) | LDHAMMP1SAE1UBA2MMP3 | |
| SCHEMBL8645164 | 0.84 | LDHA (0.57) | LDHAMMP1SAE1UBA2MMP3 | |
| SCHEMBL19545998 | 0.84 | LDHA (0.57) | LDHAMMP1SAE1UBA2MMP3 | |
| SCHEMBL2029603 | 0.84 | LDHA (0.67) | LDHAMMP1MMP3MMP9MMP2 | |
| SCHEMBL995624 | 0.84 | LDHA (0.67) | LDHAMMP1MMP3MMP9MMP2 | |
| SCHEMBL16063575 | 0.84 | LDHA (0.67) | LDHAMMP1MMP3MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | GPR68, GPR88, GPR52 | LDHA 4712/4885MMP1 4294/4885SAE1 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.